FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907552893> ?p ?o ?g. }

• W2907552893 endingPage "137" @default.
• W2907552893 startingPage "133" @default.
• W2907552893 abstract "Canadian Journal of Cardiology (CJC) enters its 35th year of publication in 2019. Founded and first edited by Dr Robert Beamish in 1985, and subsequently stewarded by Eldon Smith from 1997 until I assumed the role of Editor-in-Chief in 2010, CJC has evolved into a premier international cardiology journal. With approximately 1800 submissions in 2018, CJC had a 2017/2018 impact factor of 4.524 (a 3.4-fold increase over the 2009 value of 1.324) in the top quarter of cardiology journals, and a 5-year impact factor of 4.035. In 2017, CJC had more than 800,000 full-text article downloads and a 7.3-day average time from submission to first decision: one of the best in the area. CJC has been a pioneer in a number of areas and continues to blaze new trails. One exciting new development is the launch of our sister Open Access journal, CJC Open (CJCO). After an extensive search and careful review of a number of excellent candidates, the selection committee chose an outstanding person, Dr Michelle Graham from the University of Alberta, as the first Editor-in-Chief of CJCO. Michelle has been a consistent pioneer and trail blazer in cardiology. She was one of the first women to brave the then male-dominated area of cardiology and added “insult to injury” by excelling in the academic domain that, until then, very few women had chanced. Her contributions to cardiology in Canada and throughout the world have been exceptional. She has performed ground-breaking work in the areas of emergency cardiology, geriatric cardiovascular medicine, new models of care delivery, health care outcomes, and many others. Michelle has served the Canadian Cardiovascular Society (CCS) extensively, most notably as chair of the Guidelines Committee, for which she played a key role in organizing, structuring, and strengthening process and output. Before becoming CJCO Editor-in-Chief, Michelle Graham was an outstanding Associate Editor for CJC. I will always cherish the memory of Michelle telling me that she felt the need for a new challenge when her mandate as CCS Guidelines Committee Chair ended and asking me if I could find something for her to do at CJC. I suggested to her the possibility of joining the editorial staff as an Associate Editor. That was best decision I ever made as Editor-in-Chief of CJC. Under her stewardship, CJCO is flourishing. Since the launch of the CJCO manuscript-handling website on October 5, 2018, just more than 2 months ago, 27 papers have been submitted: 16 directly and 11 as transfers from CJC. Of these, 8 have been accepted, 5 have been rejected, 8 have received requests for revision, and 6 are in the active-review process. Of the 7 articles in the inaugural January 2019 issue, 4 are Original Research papers, 2 are Images in Cardiology articles, and 1 is a Case Report. CJCO is accepting submissions for the same article categories as CJC; full CJCO Author Guidelines are available at https://www.elsevier.com/journals/cjc-open/2589-790x/guide-for-authors. Certain types of papers may be particularly appropriate for CJCO and more difficult to get into CJC because of space limitations: for example, trial design articles, reports of health care outcomes of primarily local interest, viewpoint papers, and valuable but primarily confirmatory studies in basic or clinical science. Articles submitted to CJC that are found to be of potential value but cannot be accommodated in CJC because of insufficient page availability are offered transfer to CJCO. For situations in which the papers have already undergone primary review at CJC, if transfer to CJCO is accepted, the articles can be submitted directly as revisions to CJCO along with any necessary modifications and responses to the CJC reviews on the original submission. As CJCO is an Open Access journal, the articles published in it are fully available to all potential readers without the need for a subscription or download fee. Granting agencies are increasingly requiring Open Access publication, a development that points toward Open Access publication as the way of the future.1An explosion of openness is about to hit scientific publishing. The Economist. September 7, 2018.https://www.economist.com/open-future/2018/09/07/an-explosion-of-openness-is-about-to-hit-scientific-publishingDate accessed: December 27, 2018Google Scholar Open Access articles require a publication payment to offset the loss of revenue from subscriptions and download fees that otherwise cover publication costs. CJCO publication fees are relatively modest, running from $900 ($700 for CCS members) for Case Reports, Images, and Viewpoint articles to $2100 ($1600 for CCS members) for full Original Articles, Study Design papers, Review articles, and Systematic Review/Meta-analysis articles (all figures are in US dollars, as the CJCO publisher is based in the United States). CJCO fees are approximately 20% lower than comparable area industry average for full papers and 50% lower for Case Reports/Images/Viewpoints. For CCS members, the fees are approximately 30% lower for full articles and 68% lower for Case Reports/Images/Viewpoints. CJC is the official journal of CCS. One major component of its mission is to contribute to the academic development of young cardiovascular clinical/basic scientists in Canada. Consequently, CJC has developed—in collaboration with CCS—a series of initiatives to promote the involvement in CJC publication of trainees in Canadian cardiovascular training programs. There are 3 primary components to this training initiative. CJC has developed an article publication training program initiative, in which Canadian Cardiology Training Programs are invited to name up to 2 trainees who will submit invited papers to CJC with the assistance of a designated local academic mentor. The first cycle was completed in 2015, with 11 trainee papers published, and feedback was positive. A second cycle followed, in which 10 centres throughout Canada agreed to participate and submit a total of 18 papers between June 2016, and March 2017. Of these, 15 papers were received (9 of which were accepted; 2 were rejected, and 4 are still in revision). The first 2 cycles involved cardiology programs only; a third cycle is currently under way, involving cardiac surgery and pediatric cardiology programs in addition to cardiology. For the current cycle, 13 centres are participating, with 36 articles projected; 15 have already been submitted, and 21 more are to be submitted through the spring of 2019. CJC has initiated a program to include Canadian cardiovascular trainees as trainee members of the CJC Editorial Board or reviewer database. Each trainee has a mentor—in most cases, a member in good standing of the CJC editorial board—to support the trainee in article review and help to ensure quality control. We received 25 excellent applications in response to a call in 2016. After thorough grading by a selection committee, 7 trainees were selected as Trainee Editorial Board Members and 18 were added as trainee members of the CJC reviewer database. Their mandates began in January 2017 and ended in December 2018. The 7 trainee editorial board members reviewed an annual median of 12 papers (range 6 to 22) with a median time from review assignment to completion of 6 days (range of average times 0 to 12 days). The trainee reviewers reviewed a median of 5 papers per year (range 0 to 21) with a median turnover time of 7.5 days (range 2 to 13). Feedback from reviewers and mentors about the interest of the program and its value to trainees was positive. The quality of trainee reviews was evaluated by the CJC editorial staff as varying from “very good” to “outstanding.” A new set of 7 trainee editorial board members was selected in the fall of 2018, including—for the first time—2 CCS members-in-training engaged in overseas cardiology fellowships, along with 22 trainee reviewers; they will begin their 2-year terms in January 2019, and we look forward to continued success of this innovative program. CCS and CJC have initiated a Trainee Section that is run by trainees, with articles of particular interest for trainees written by trainees that deal with such matters as challenges in training, helpful advice for trainees, and trainee-oriented discussions. The Trainee Section appears in the CCS Society Pages of the journal and is managed by a committee consisting of 2 trainee co-editors (Jacinthe Leclerc and Erin Rayner-Hartley) and 2 faculty supervisors (Paul Poirier and Parvathy Nair). Seven articles have appeared in this section to date. CJC has developed a special interest in congenital heart disease (CHD) and pediatric cardiology. These are subjects in particularly rapid growth and are, in our opinion, somewhat underserved in the current cardiology literature. Dr Kevin Harris, of the University of British Columbia, has been identified as a particularly valuable resource person in this area and has been recruited as an Associate Editor for CJC. Between June 2018, and now (December 2018), CJC has published 38 articles dealing with CHD and/or pediatric heart disease as the primary focus, constituting 17.6% of all CJC papers in this period. Space does not permit a full summary of these papers here, but we will briefly mention the content of selected articles to give a sense of some of the areas touched upon. CHD is the most common birth defect, complicating about 1% of live births.2Harris K.C. Congenital heart disease: surgical repair is just the beginning.Can J Cardiol. 2018; 34: 1250-1252Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar Islam et al used the Alberta Pregnancy-Birth Cohort to perform a population-based analysis of health care utilization among almost 450,000 children born in Alberta between 2005 and 2014, including almost 7000 with CHD.3Islam S. Kaul P. Tran D.T. Mackie A.S. Health care resource utilization among children with congenital heart disease: a population-based study.Can J Cardiol. 2018; 34: 1289-1297Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar The rate of hospitalization in the first year of life (excluding birth hospitalizations) averaged 235 per 100 children with single-ventricle physiology, 100 in moderate to complex CHD, 52 in simple CHD, and 9 in children without CHD. Outpatient visits during the first year followed a similar trend, with 4871 per 100 children with single-ventricle, 2278 for moderate to complex, and 1416 with simple CHD vs 246 per 100 children without CHD. The health care resource implications of these findings are clearly enormous, requiring strategies to optimize long-term care and resource planning for the CHD population and in the context of rapidly advancing health care technologies.2Harris K.C. Congenital heart disease: surgical repair is just the beginning.Can J Cardiol. 2018; 34: 1250-1252Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar Beland et al review the history of CHD nomenclature in Canada and propose the adoption of a diagnostic list put forward by the International Society for Nomenclature of Paediatric and Congenital Heart Disease.4Arslani K. Roffler N. Zurek M. et al.SACHER Investigators. Patterns of incidence rates of cardiac complications in patients with congenital heart disease.Can J Cardiol. 2018; 34: 1624-1630Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar They also provide French-equivalent terms for all diagnoses, important for national research programs in a bilingual country such as Canada. Arslani et al review the time course and occurrence of cardiac complications of CHD (including atrial fibrillation [AF] and/or flutter, ventricular tachycardia, atrioventricular [AV] block, heart failure, endocarditis, stroke, myocardial ischemia/infarction, and pulmonary hypertension) among 2731 patients with CHD.5Béland M.J. Harris K.C. Marelli A.J. Houyel L. Bailliard F. Dallaire F. Improving quality of congenital heart disease research in Canada: standardizing nomenclature across Canada.Can J Cardiol. 2018; 34: 1674-1676Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar Just under one third (28%) had at least 1 complication. More than two thirds of complications occurred in adult life (> 18 years old); however, certain complications—such as perioperative stroke and complete AV block—were more common in childhood. Atrial tachyarrhythmias are an important complication of CHD, with increasing rates of AF after age 50. In the CJC Theme Issue on AF, Ebrahim et al provide a contemporary review of the mechanisms, epidemiology, and treatment aspects of AF in patients with CHD.6Ebrahim M.A. Escudero C.A. Kantoch M.J. Vondermuhll I.F. Atallah J. Insights on atrial fibrillation in congenital heart disease.Can J Cardiol. 2018; 34: 1531-1533Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar Reiner et al analyze the early precursors of an increasingly recognized complication of CHD: atherosclerotic heart disease.7Reiner B. Oberhoffer R. Häcker A.L. Ewert P. Müller J. Carotid intima-media thickness in children and adolescents with congenital heart disease.Can J Cardiol. 2018; 34: 1618-1623Abstract Full Text Full Text PDF PubMed Scopus (11) Google Scholar They find increased carotid intimal-medial thickness in children with CHD vs age-matched controls, with the largest values associated with aortic coarctation and congenital transposition of the great arteries with arterial switch procedures. A series of articles deal with congenital and pediatric coronary artery abnormalities. Kukuchi et al describe a case in which accelerated atherosclerosis caused by a congenital myocardial bridge led to myocardial infarction.8Kikuchi S. Okada K. Hibi K. et al.Myocardial infarction caused by accelerated plaque formation related to myocardial bridge in a young man.Can J Cardiol. 2018; 34: 1687.e13-1687.e15Abstract Full Text Full Text PDF Scopus (9) Google Scholar Isorni et al describe the unusual coexistence of 3 different types of congenital coronary abnormality in a single patient.9Isorni M.A. Amato A. Guihaire J. Unusual association of three types of congenital coronary artery diseases.Can J Cardiol. 2018; 34: 1233.e5-1233.e8Abstract Full Text Full Text PDF Scopus (1) Google Scholar Kawasaki disease is an inflammatory vasculitis occurring in children, with coronary artery involvement in approximately 25% of patients not given anti-inflammatory therapy vs approximately 4% of treated patients.10McCrindle B.W. Harris K.C. Coronary artery aneurysms after Kawasaki disease: understanding the pathology.Can J Cardiol. 2018; 34: 1094-1097Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar Coronary artery aneurysms are a common complication. Dionne et al describe the use of optical coherence tomography to study the underlying pathophysiology of coronary artery involvement, with fibrosis, cellular infiltration, and intimal hyperplasia being ubiquitous findings and calcification, medial necrosis, neovascularization, and thrombus formation strongly associated with the development of aneurysms.11Dionne A. Ibrahim R. Gebhard C. et al.Difference between persistent aneurysm, regressed aneurysm, and coronary dilation in Kawasaki disease: an optical coherence tomography study.Can J Cardiol. 2018; 34: 1120-1128Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar Familial hypercholesterolemia (FH) due to mutations in lipid-metabolism proteins is the most common cause of premature atherosclerosis. To be optimally effective, treatment should begin in childhood, around age 10.12McPherson R. The cardiovascular burden of undiagnosed familial hypercholesterolemia: need to modify guidelines to encourage earlier diagnosis and therapy.Can J Cardiol. 2018; 34: 1112-1113Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar Perhaps because of the complexity and difficult accessibility of some of the criteria needed to diagnose FH according to standard criteria, many cases go unrecognized until it is too late. Ruel et al propose a simplified diagnostic definition for FH based on the distribution of low-density lipoprotein cholesterol levels.13Ruel I. Brisson D. Aljenedil S. et al.Simplified Canadian definition for familial hypercholesterolemia.Can J Cardiol. 2018; 34: 1210-1214Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar The definition is adapted to the Canadian medical context and has the potential to lead to earlier diagnosis and therapy, a critical concern.12McPherson R. The cardiovascular burden of undiagnosed familial hypercholesterolemia: need to modify guidelines to encourage earlier diagnosis and therapy.Can J Cardiol. 2018; 34: 1112-1113Abstract Full Text Full Text PDF PubMed Scopus (4) Google Scholar Brunham et al provide an updated CCS Position Statement on FH.14Brunham L.R. Ruel I. Aljenedil S. et al.Canadian Cardiovascular Society position statement on familial hypercholesterolemia: update 2018.Can J Cardiol. 2018; 34: 1553-1563Abstract Full Text Full Text PDF PubMed Scopus (65) Google Scholar Among other aspects, they provide guidance for early diagnosis; the use of statins, ezetimibe and PCSK9 inhibitors; and improved health care delivery by translation of knowledge, mobilization of patient sensitization/support, and optimal provision of resources. They emphasize the fact that the risk of atherosclerotic heart disease is increased 10- to 20-fold by FH, whereas initiation of treatment in childhood or in young adults can normalize life expectancy. Razek et al review the efficacy of PCSK9 inhibitors in FH, highlighting the importance of their optimal use if needed to obtain good control of cholesterol in this high-risk population.15Razek O. Cermakova L. Armani H. et al.Attainment of recommended lipid targets in patients with familial hypercholesterolemia: real-world experience with PCSK9 inhibitors.Can J Cardiol. 2018; 34: 1004-1009Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar Several studies provided novel insights into the genetic basis of CHD. Iacocca et al describe a familial FH syndrome involving extremely high LDL cholesterol and PCSK9 levels and severe resistance to statin therapy due to a duplication in the PCSK9 gene.16Iacocca M.A. Wang J. Sarkar S. et al.Whole-gene duplication of PCSK9 as a novel genetic mechanism for severe familial hypercholesterolemia.Can J Cardiol. 2018; 34: 1316-1324Abstract Full Text Full Text PDF PubMed Scopus (29) Google Scholar This finding has important implications for the understanding of FH and for the management of affected persons.17Paquette M. Baass A. A novel cause of familial hypercholesterolemia: PCSK9 gene duplication.Can J Cardiol. 2018; 34: 1259-1260Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar Greenway et al describe a therapeutic trial of digoxin, showing striking efficacy for improving cardiac function in patients with a rare form of mitochondrial cardiomyopathy, the dilated cardiomyopathy with ataxia (DCMA) syndrome caused by mutations in DNAJC19, which encodes a protein that is part of a complex implicated in ATP-dependent transport of chaperone proteins from the inner-cell membrane to the mitochondrial matrix.18Greenway S.C. Dallaire F. Hazari H. Patel D. Khan A. Addition of digoxin improves cardiac function in children with the dilated cardiomyopathy with ataxia syndrome: a mitochondrial cardiomyopathy.Can J Cardiol. 2018; 34: 972-977Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar In an accompanying editorial, Song et al underline the therapeutic and conceptual importance of these findings and the potential to lead to advances in our understanding of the pathophysiology of mitochondrial cardiomyopathies.19Kizawa M. Nakagama Y. Shindo T. Ogawa S. Inuzuka R. Identification of a novel titin variant underlying myocardial involvement in neurofibromatosis type 1.Can J Cardiol. 2018; 34: 1369.e5-1369.e7Abstract Full Text Full Text PDF Scopus (2) Google Scholar The co-occurrence of cardiomyopathy with neurofibromatosis is rare. Kizawa et el describe a 2-year-old child with genetically based neurofibromatosis and restrictive cardiomyopathy, who proved to have an independent mutation in a titin gene causing the cardiomyopathy.20Song A.T. Joyal J.S. Andelfinger G. The power of rare: an opportunity to repurpose an old drug for mitochondrial cardiomyopathy.Can J Cardiol. 2018; 34: 950-952Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar A number of studies deal with novel diagnostic and therapeutic approaches. Hazari et al compare echocardiography and cardiac magnetic resonance (CMR) imaging in the longitudinal evaluation of myocardial mass in patients with Fabry disease.21Hazari H. Belenkie I. Kryski A. et al.Comparison of cardiac magnetic resonance imaging and echocardiography in assessment of left ventricular hypertrophy in Fabry disease.Can J Cardiol. 2018; 34: 1041-1047Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar They note that left ventricular mass, as measured by CMR, increases with the development of cardiac fibrosis and that enzyme-replacement therapy slows these changes, pointing to the value of this indicator. Kato et al apply automated, real-time 3-dimensional volume colour-flow Doppler echocardiography to obtain single-beat right-heart flow measurements in children with atrial shunts.22Kato A. Sandoval J.P. Mroczek D. et al.Automated 3-dimensional single-beat real-time volume colour flow Doppler echocardiography in children: a validation study of right and left heart flows.Can J Cardiol. 2018; 34: 726-735Abstract Full Text Full Text PDF PubMed Scopus (6) Google Scholar The feasibility of single-beat right-sided stroke-volume measurements provides a potentially valuable noninvasive index for children with CHD. Kowalik et al evaluate the use of several candidate biomarkers in predicting outcomes in adults (mean age: 36) with congenitally corrected transposition of the great arteries, concluding that a combination of high-sensitivity troponin values and systemic right-ventricular end-diastolic areas is the best predictor of adverse cardiovascular outcomes, with an area under the receiver-operating curve (AUC) of 0.79.23Kowalik E. Klisiewicz A. Kowalski M. et al.High-sensitive cardiac troponin T and systemic right ventricular area predict outcomes in adults with congenitally corrected transposition.Can J Cardiol. 2018; 34: 1129-1136Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar Moceri et al describe changes in right-ventricular function during pregnancy in repaired tetralogy of Fallot, indicating the potential value in counselling and follow-up.24Moceri P. Sermesant M. Baudouy D. Ferrari E. Duchateau N. Right ventricular function evolution with pregnancy in repaired tetralogy of Fallot.Can J Cardiol. 2018; 34 (1369.e9-1369.e11)Abstract Full Text Full Text PDF PubMed Scopus (1) Google Scholar The Ross procedure, involving the use of pulmonary valve autografts in the aortic valve position in conjunction with pulmonary valve bioprosthesis placement, is increasingly being used in the management of aortic stenosis, particularly because of congenital bicuspid valves in young adults.25Ghoneim A. Bouhout I. Losenno K. et al.Expanding eligibility for the Ross procedure: a reasonable proposition?.Can J Cardiol. 2018; 34: 759-765Abstract Full Text Full Text PDF PubMed Scopus (5) Google Scholar Kellermair et al describe the case of 51-year-old man who had undergone a Ross procedure for congenital aortic stenosis and presented with severe right ventricle-to-pulmonary artery conduit stenosis/regurgitation. A Melody-system pulmonic valve (Melody Transcatheter Pulmonary Valve, Medtronic, Fridley, Minnesota) was implanted via a transcatheter approach; the patient developed severe signs of right-ventricular outlet obstruction due to prosthetic-valve thrombosis within 24 hours, which ultimately required surgical valve replacement.26Kellermair J. Roland G. Rudolf M. Matthias S. Michael G. Clemens S. First report of an acute, obstructive thrombosis of a Melody valve used for transcatheter pulmonary replacement.Can J Cardiol. 2018; 34: 1688.e13-1688.e15Abstract Full Text Full Text PDF Scopus (1) Google Scholar The thrombus was related to a heterozygous prothrombin G20210A polymorphism associated with a homozygous 4G/4G polymorphism of the plasminogen-activator-inhibitor. Jalal et al report a challenging case in which the rapidly evolving novel method of 3-dimensional printing was used to allow successful implantation of a Hybrid Melody valve through a transeptal approach via right atriotomy in a 4-month-old child with an atrioventricular canal abnormality and 3 previous failed surgeries.27Jalal Z. Seguela P.E. Iriart X. et al.Hybrid Melody valve implantation in mitral position in a child: usefulness of a 3-dimensional printed model for preprocedural planning.Can J Cardiol. 2018; 34: 812.e5-812.e7Abstract Full Text Full Text PDF Scopus (4) Google Scholar With all the medical issues surrounding the management of CHD, the associated psychosocial burden receives relatively limited attention. Patients with CHD have increased incidence of anxiety, depression, and other psychiatric/psychosocial problems.28Mackie A.S. Body and mind: psychosocial interventions for adults with congenital heart disease.Can J Cardiol. 2018; 34: 698-699Abstract Full Text Full Text PDF PubMed Scopus (2) Google Scholar These may lead to limited physical activity levels, which have deleterious effects on both mental and physical health. Cardiac rehabilitation can be an important tool in combating these issues but presents particular challenges in the CHD population.29Kovacs A.H. Kaufman T.M. Broberg C.S. Cardiac rehabilitation for adults with congenital heart disease: physical and psychosocial considerations.Can J Cardiol. 2018; 34: S270-S277Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar In addition, it might be possible to combat these limitations with active psychosocial intervention. Kovacs et al provide the findings of a pilot study for a randomized controlled trial assessing the effectiveness of psychosocial intervention, showing both the feasibility and potential promise of this approach.30Kovacs A.H. Grace S.L. Kentner A.C. Nolan R.P. Silversides C.K. Irvine M.J. Feasibility and outcomes in a pilot randomized controlled trial of a psychosocial intervention for adults with congenital heart disease.Can J Cardiol. 2018; 34: 766-773Abstract Full Text Full Text PDF PubMed Scopus (18) Google Scholar Moving forward, we plan to continue the emphasis on CHD and pediatric cardiology in CJC. A theme issue on adult CHD is planned for the fall of 2019 and, in addition to state-of-the-art review articles in the area, will feature a CCS Guidelines report in the area. CJC is growing and succeeding. With the addition of CJC Open, the scope and range of CCS publications has expanded. We look forward to further expansion in congenital heart disease, pediatrics, and other rapidly developing and exciting areas in cardiology." @default.
• W2907552893 created "2019-01-11" @default.
• W2907552893 creator A5064311226 @default.
• W2907552893 date "2019-02-01" @default.
• W2907552893 modified "2023-10-02" @default.
• W2907552893 title "The Canadian Journal of Cardiology: Open and Growing" @default.
• W2907552893 cites W2786900019 @default.
• W2907552893 cites W2788703650 @default.
• W2907552893 cites W2789028586 @default.
• W2907552893 cites W2791284893 @default.
• W2907552893 cites W2793711712 @default.
• W2907552893 cites W2794535757 @default.
• W2907552893 cites W2801034365 @default.
• W2907552893 cites W2801776797 @default.
• W2907552893 cites W2803057033 @default.
• W2907552893 cites W2804048509 @default.
• W2907552893 cites W2805531471 @default.
• W2907552893 cites W2805657234 @default.
• W2907552893 cites W2810593489 @default.
• W2907552893 cites W2810958374 @default.
• W2907552893 cites W2835370860 @default.
• W2907552893 cites W2883851249 @default.
• W2907552893 cites W2883874086 @default.
• W2907552893 cites W2883934715 @default.
• W2907552893 cites W2884492287 @default.
• W2907552893 cites W2885102746 @default.
• W2907552893 cites W2887373613 @default.
• W2907552893 cites W2887397898 @default.
• W2907552893 cites W2887565581 @default.
• W2907552893 cites W2888555783 @default.
• W2907552893 cites W2888724302 @default.
• W2907552893 cites W2889195868 @default.
• W2907552893 cites W2894456543 @default.
• W2907552893 cites W2894643842 @default.
• W2907552893 cites W2902955133 @default.
• W2907552893 doi "https://doi.org/10.1016/j.cjca.2018.12.037" @default.
• W2907552893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30760416" @default.
• W2907552893 hasPublicationYear "2019" @default.
• W2907552893 type Work @default.
• W2907552893 sameAs 2907552893 @default.
• W2907552893 citedByCount "0" @default.
• W2907552893 crossrefType "journal-article" @default.
• W2907552893 hasAuthorship W2907552893A5064311226 @default.
• W2907552893 hasBestOaLocation W29075528931 @default.
• W2907552893 hasConcept C126322002 @default.
• W2907552893 hasConcept C164705383 @default.
• W2907552893 hasConcept C71924100 @default.
• W2907552893 hasConceptScore W2907552893C126322002 @default.
• W2907552893 hasConceptScore W2907552893C164705383 @default.
• W2907552893 hasConceptScore W2907552893C71924100 @default.
• W2907552893 hasFunder F4320334506 @default.
• W2907552893 hasIssue "2" @default.
• W2907552893 hasLocation W29075528931 @default.
• W2907552893 hasLocation W29075528932 @default.
• W2907552893 hasOpenAccess W2907552893 @default.
• W2907552893 hasPrimaryLocation W29075528931 @default.
• W2907552893 hasRelatedWork W2011347913 @default.
• W2907552893 hasRelatedWork W2049397185 @default.
• W2907552893 hasRelatedWork W2073151595 @default.
• W2907552893 hasRelatedWork W2074833529 @default.
• W2907552893 hasRelatedWork W2125804349 @default.
• W2907552893 hasRelatedWork W2159512267 @default.
• W2907552893 hasRelatedWork W2304633692 @default.
• W2907552893 hasRelatedWork W2355498105 @default.
• W2907552893 hasRelatedWork W2399063111 @default.
• W2907552893 hasRelatedWork W2414320482 @default.
• W2907552893 hasVolume "35" @default.
• W2907552893 isParatext "false" @default.
• W2907552893 isRetracted "false" @default.
• W2907552893 magId "2907552893" @default.
• W2907552893 workType "article" @default.